Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Advances in Therapy"
DOI: 10.1007/s12325-020-01394-y
Abstract: Introduction Currently available second-line (2L) therapies for advanced/metastatic esophageal squamous cell carcinoma (adv/met ESCC) include the taxanes paclitaxel and docetaxel. In clinical trials, such therapies have provided only modest improvements in survival. Few studies have… read more here.
Keywords: advanced metastatic; metastatic esophageal; patients receiving; adv met ... See more keywords
Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e16035
Abstract: e16035Background: Few studies have examined the economic burden of adv/met GC/GEJC in the US. This analysis assessed real-world treatment patterns, healthcare resource utilization (HRU), and costs ... read more here.
Keywords: treatment utilization; understanding treatment; adv; adv met ... See more keywords